Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 12/20 | 1.00 |
| ▸ | TOP1 | P11387 | 1/20 | 0.91 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | CRHBP | P24387 | 1/20 | 0.78 |
| ▸ | CASP7 | P55210 | 1/20 | 0.78 |
| ▸ | CASP6 | P55212 | 1/20 | 0.78 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.78 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.72 |
| ▸ | GALK1 | P51570 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7355113 | 0.97 | NQO1 (0.94) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL4385323 | 0.95 | NQO1 (1.00) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL14172083 | 0.91 | NQO1 (1.00) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL1649097 | 0.89 | NQO1 (1.00) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL7909128 | 0.88 | NQO1 (0.86) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL12028810 | 0.88 | NQO1 (0.86) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL4390609 | 0.88 | NQO1 (1.00) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL7899682 | 0.88 | NQO1 (0.86) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL7898320 | 0.88 | NQO1 (0.86) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL14170434 | 0.88 | NQO1 (0.81) | NQO1TOP1CYP2C9CRHBPCASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112645922-B | Coumarin compound, preparation method and application | 中国人民解放军空军军医大学 | 2022-01-07 | — | — | CN | disclosed |
| CN-112645922-A | Coumarin compound, preparation method and application | 中国人民解放军空军军医大学 | 2021-04-13 | — | — | CN | disclosed |
| CN-110256390-B | Coumarin compound, preparation method and application of coumarin compound in preparation of medicine for treating cerebral apoplexy | 中国人民解放军第四军医大学 | 2020-11-24 | — | — | CN | disclosed |
| CN-110256390-A | The application of coumarin kind compound, preparation method and preparation treatment cerebral apoplexy drug | 中国人民解放军第四军医大学 | 2019-09-20 | — | — | CN | disclosed |
| CN-108774204-A | 3,3 '-(3,5 difluoro benzylidene)-bis- -4 hydroxy coumarins and its application | 中国人民解放军第四军医大学 | 2018-11-09 | — | — | CN | disclosed |
| US-20150133493-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER | 2015-05-14 | — | — | US | disclosed |
| US-20150133493-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER | 2015-05-14 | — | — | US | disclosed |
| US-20110306605-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306605-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2010075280-A2 | COUMARIN-BASED COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20090124688-A1 | Prostaglandin reductase inhibitors | ABGENOMICS CORPORATION (TW) | 2009-05-14 | — | — | US | disclosed |
| US-20090124688-A1 | Prostaglandin reductase inhibitors | ABGENOMICS CORPORATION (TW) | 2009-05-14 | — | — | US | disclosed |
| WO-2007082178-A2 | PROSTAGLANDIN REDUCTASE INHIBITORS | ABGENOMICS CORPORATION (TW) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133493-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | BACE1, PSEN1, APP | NQO1 174/4885TOP1 431/4885CYP2C9 877/4885 |
| US-20110306605-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | BACE1, PSEN1, APP | NQO1 174/4885TOP1 431/4885CYP2C9 877/4885 |
| US-20090124688-A1 | Prostaglandin reductase inhibitors | PTGIR, PTGDR, PTGDR2 | NQO1 594/4885TOP1 3380/4885CYP2C9 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.